Targeting the B cell receptor (BCR) signalling pathway, particularly through inhibiting Bruton's tyrosine kinase (BTK), has dramatically transformed the lives of patients with CLL. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.